Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia - BioSpace

<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxOWExCRzZ6Rm52RFFRT0…; target="_blank">Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia</a>&nbsp;&nbsp;<font color="#6f6f6f">BioSpace</font>